NEWS AND EVENTS
November 30, 2023
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
Learn MoreNeurogene / Neoleukin Conference Call Discussing Merger Agreement to Create Clinical-Stage Company Focused on Differentiated Portfolio of Genetic Medicines for Complex Neurological Diseases
Learn MoreJanuary 23, 2023
Neurogene Announces FDA Clearance of IND for NGN-401 Gene Therapy for Children with Rett Syndrome
Learn MoreMay 18, 2022
Neurogene Announces New Development Program in Rett Syndrome Utilizing Novel EXACT Technology Platform
Learn MoreSeptember 14, 2021
Neurogene Announces FDA Clearance of IND for NGN-101 Gene Therapy to Treat CLN5 Batten Disease
Learn MoreJune 29, 2021
Neurogene Announces EMA Grants Orphan Drug Designation to CLN5 Batten Disease Gene Therapy
Learn MoreMay 11, 2021
Neurogene’s AAV Biodistribution Study Shows Route of Administration Essential Component in Optimizing Gene Therapy Treatment for Neurological Disease
Learn MoreJanuary 18, 2021
Neurogene and University of Edinburgh Announce Research Collaboration to Advance Next Generation Gene Therapies
Learn MoreDecember 2, 2020
Neurogene Announces EMA Grants Orphan Drug Designation for Aspartylglucosaminuria Gene Therapy
Learn MoreNovember 12, 2020
Neurogene Announces First Patient Enrolled in Natural History Study Evaluating Two Subtypes of Batten Disease
Learn MoreSeptember 16, 2020
Neurogene Appoints Industry Veteran Robert A. Baffi, Ph.D. to Board of Directors
Learn MoreAugust 11, 2020
Neurogene Announces FDA Orphan Drug Designation for CLN7 Batten Disease Gene Therapy
Learn MoreJuly 5, 2020
FDA Grants Orphan Drug Designation to Neurogene’s Gene Therapy for the Treatment of CLN5 Batten Disease
Learn MoreFebruary 10, 2020
Neurogene Joins Behind the Seizure® Program, Sponsors Genetic Testing for Children with Seizures
Learn MoreJuly 25, 2019
Neurogene Offers Access to Genetic Testing to Patients Suspected of Having a Lysosomal Storage Disease
Learn MoreJuly 18, 2019
Neurogene Initiates Natural History Study of Charcot-Marie Tooth Disease (CMT4J)
Learn MoreFebruary 27, 2019
Neurogene Appoints Industry Leaders Dr. Sukumar Nagendran and Dr. Serge Stankovic to Board of Directors
Learn MoreFebruary 12, 2019
Neurogene Raises $68.5 Million in Series A Financing to Advance Multiple Programs in Devastating Neurological Diseases
Learn MoreFebruary 7, 2019
Neurogene Announces Presentation of Preclinical Data for Gene Therapies to Treat AGU and CMT4J, Two Rare and Devastating Neurodegenerative Disorders
Learn More